DUBLIN–(BUSINESS WIRE)–The “CRISPR and Cas Genes Market Size, Share & Trends Analysis Report by End-use (CROs, Biotech & Pharma Companies), by Application (Biomedical, Agriculture), by Product & Service, by Region, and Segment Forecasts, 2022-2030” report has been added to ResearchAndMarkets.com’s offering.
The global CRISPR and Cas genes market size is expected to reach USD 9.6 billion by 2030. The market is expected to register a CAGR of 17.9% during the forecast period, owing to the increasing usage of CRISPR and Cas genes systems in the biomedical research field. The use of CRISPR-Cas systems in diagnostics and the assessment of evolutionary analysis in prokaryotes has significantly increased, owing to the developments in the field of genome editing. The application of this technology enables easy and cost-efficient editing of genes. Genome editing has made a significant advancement in biomedical research, with the present trend of cutting-edge techniques paving the way for the future treatment of different genetic and non-genetic disorders.
The development and implementation of more effective ways for gene targeting and the generation of gene-edited avian species have been facilitated by the availability of the CRISPR/Cas9-mediated gene and genome editing technology. According to an article published on Frontiers in February 2021, CRISPR/Cas9 has become a robust and important tool for gene editing in the poultry industry. Potential applications in several fields would further boost the demand for this technology. The COVID-19 outbreak shifted the researcher’s emphasis to the development of COVID-19 molecular diagnostic tools based on this technology. For instance, in March 2021, Nanyang Technological University researchers in Singapore created a COVID-19 test based on CRISPR that provides results in 30 minutes.
Even after the virus has mutated, this test still discovers it. This would further encourage the other key players to leverage this technique, thereby driving the industry’s growth. This technology is increasingly being used for several medical and other applications.
Competition over patents for such a gene-editing technology is expected to grow, as more academic institutions and biotech companies attempt to develop new commercial applications of this technology. In addition, there is a lot of potential for this technique to advance with the use of machine learning technologies. For instance, in August 2022, Synthego launched engineered cell libraries, a cutting-edge service that expands access to CRISPR by giving arrayed CRISPR-edited cells for use directly in functional screening experiments.
It has potential applications in disease research. Key players offer tools and solutions for each step of the gene editing workflow. Integrating several tools, services, and improved processes makes it possible to complete research experiments rapidly and with little effort. Moreover, key players have raised significant funding to support the R&D of the CRISPR & Cas9 gene-editing approach. For instance, in April 2021, Vertex Pharmaceuticals collaborated with CRISPR Therapeutics to develop and manufacture a new CRISPR/Cas9-based gene editing therapy called CTX001, a potential therapeutic option for transfusion-dependent beta-thalassemia and Sickle Cell Disease (SCD). In January 2020, Mammoth Biosciences raised USD 45 million to develop next-gen CRISPR products for therapeutics & diagnostics purposes. This would further be used to develop the company’s CRISPR genes-driven diagnostics portfolio.
Market Dynamics
Market Drivers
Growing Need For Novel Therapeutics
Rising Demand For Gene Editing
Rising Incidence Of Cancer
Market Restraints
Off-Target Effects Of CRISPR Technology
High-Cost Factor, Intellectual Property Disputes & Ethical Dilemma
Key Topics Covered:
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Crispr & Cas Genes Market Variables, Trends And Scope
Chapter 4 Product & Service Business Analysis
Chapter 5 Application Business Analysis
Chapter 6 End-Use Business Analysis
Chapter 7 Market Categorization: Regional Estimates & Trend Analysis by Product, Application & End-use
Chapter 8 Competitive Landscape
Companies Mentioned
Caribou Biosciences
Astrazeneca
Intellia Therapeutics, Inc.
Addgene
Crispr Therapeutics
New England Biolabs
Thermo Fisher Scientific, Inc.
Synthego
Mammoth Biosciences
Inscripta, Inc.
Cibus
Beam Therapeutics
Plantedit
Vertex Pharmaceuticals Incorporated
Genscript
Integrated Dna Technologies
Lonza
Merck
Hera Biolabs
Origene Technologies, Inc.
Recombinetics, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/xxmz0k
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
